Chief Financial Officer · Lexeo Therapeutics, Inc. · Lexeo Therapeutics, Inc. — Stock Option (right to buy)
Side
A
Value
—
Shares
54.8K
Price
—
Executed
Sep 24, 2026
Disclosed
Sep 28, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Sep 24 executedSep 28, 2026 disclosed
LXEO · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Lexeo Therapeutics, Inc. — Stock Option (right to buy)
Ticker
LXEO
Shares
54.8K
Price per share
$0
Execution date (reported)
Sep 24, 2026
Owned after transaction
54.8K shares
Days from execution to publication
4
What this establishes
Tamayo Louis Edward filed this Form 4 reporting a grant or award of LXEO on Sep 24, 2026. It became public on Sep 28, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Chief Financial Officer
Tamayo Louis Edwardcik:0002083206
Issuer
Lexeo Therapeutics, Inc.cik:0001907108
Revision history · 0
No field has changed since this record was first ingested.
